Navigation Links
Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
Date:3/19/2008

- Additional data presentation on picoplatin overcoming platinum resistance

in small cell lung cancer -

SOUTH SAN FRANCISCO, Calif., March 19 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that preliminary data from a Phase 1 trial of an oral formulation of picoplatin in patients with solid tumors will be presented at the 2008 American Association for Cancer Research meeting to be held from April 12-16 in San Diego, CA. In addition, preclinical data of picoplatin overcoming platinum resistant small cell lung cancer cells in platinum resistant cell lines will also be presented at a separate poster presentation.

Details are as follows:

-- A Phase 1 randomized crossover picoplatin bioavailability

pharmacokinetics and pharmacodynamics study.

Abstract #209, Session ID: Clinical Research 1;

Yee L, Sharma S, Breitz H, Karlin D, Phillips A, Houston S, Saleh M.

General Poster Session Sunday April 13, 8:00 AM PT.

-- Picoplatin overcomes resistance in small cell lung cancer cell lines

treated with other platinum-based chemotherapeutics.

Abstract #713, Session ID: Experimental Molecular Therapeutics 3;

Parham C, Shocron E, McMahon G, Patel N.

General Poster Session Sunday April 13, 8:00 AM PT.

Picoplatin is the Company's lead product candidate under investigation in three clinical trials.

About Picoplatin

Picoplatin is a chemotherapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...LIN, Mass., Nov. 26 PLC ... today that it has received full approval from the....S. pivotal trial to study the effectiveness of th...therapy in the prevention of Contrast-Induced Neph...C,s request to expand their investigation from the...
(Date:11/25/2008)...e-FirstCall/ -- Poniard,Pharmaceuticals, Inc. (Na...d on,innovative oncology therapies, announced tod...es for its preclinical research programs in order ...e clinical development of picoplatin,its lead pr...cialization of,picoplatin in the treatment of sma...
(Date:11/24/2008)...o,s Pizza (NYSE: DPZ ), the,recognized world le...gh for,the kids of St. Jude Children,s Research H... campaign. Domino,s customers will have the opport...benefit the children of St. Jude.,Donations can b...ng online at, www.dominos.com . The campaign begi...
(Date:11/24/2008).../ -- Schering-Plough Corporation (NYSE: SGP ) to...tive adenosine2a receptor antagonist, met the prim...atients suffering from moderate to severe Parkinso...normal involuntary movements (dyskinesias). The t... 2008 R&D Update meeting being hosted for anal...
Breaking Medicine Technology:PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 1Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 2Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression 913 3ATV Injuries on the Rise 6905 1ATV Injuries on the Rise 6905 2ATV Injuries on the Rise 6905 3Environmental exodus 1331 1Environmental exodus 1331 2Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 1Rutgers College of Nursing faculty member Rachel Jones awarded Rutgers Newark Provost Award 6903 2
...sults Presented At ASCO -- , CHICAGO – June ... interferon alfa-2b in stage III melanoma had a,si...vival (RFS),according to the results of the large...stage III melanoma. Results of the Phase,III study...h and,Treatment of Cancer (EORTC) and supported by...
...007 - MGI Pharma, Inc.,(Nasdaq:MOGN), a biopharmac..., today provided highlights of data presentations ...Oncology (ASCO) Annual,Meeting. Dacogen (decitabin...ncluding the presentation of efficacy data in olde...nd activity,observed in patients with refractory a...
Other Medicine Technology:Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 2Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 3Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 4Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III,Melanoma Demonstrated Significant and Sustained Impact on,Relapse-Free Survival 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 2MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 3MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 4MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 5MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 6MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 7MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 8MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 9MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting 10
(Date:12/1/2008)... are developing a wide variety of arm, wrist and h...ly described gymnastic-related trauma, according t... the Radiological Society of North America (RSNA)....s unusual and might point to something new going o...thletes in different ways," said the study,s lead ...
(Date:12/1/2008)...n the Dec. 1 issue of the journal Sleep is the f...exposure strongly modify sleep patterns in preterm...or developmental difficulties that could persist t... indicate that preterm neonates born to heavy-smok... day displayed disrupted sleep structure and sleep...
(Date:11/30/2008)...Newswire/ -- Combining an ultrasound-guided techni... at relieving the common and painful foot problem ...sented today at the annual meeting of the Radiolog..."There is no widely accepted therapy or standard o...l to relieve the pain of plantar fasciitis," said ...
(Date:11/30/2008)... 1 Faint magnetic,sign...ow that those children,process sound and language...ng,and classifying these brain response patterns ... autism and possibly aid in developing more effect... Timing appears to be crucial. "Children wit...
Breaking Medicine News(10 mins):Health News:MRI shows new types of injuries in young gymnasts 2Health News:High levels of prenatal smoking exposure affect sleep patterns in preterm neonates 2Health News:High levels of prenatal smoking exposure affect sleep patterns in preterm neonates 3Health News:New Treatment Eliminates Heel Pain Caused by Plantar Fasciitis 2Health News:New Treatment Eliminates Heel Pain Caused by Plantar Fasciitis 3Health News:Brain's Magnetic Fields Reveal Language Delays in Autism 2Health News:Brain's Magnetic Fields Reveal Language Delays in Autism 3
...neers have announced that they have created a comp...he topical microbicides// used by women for preven...cides are needed since the infections globally are... physics and chemistry, the researchers developed ...
...ren's Research Hospital have discovered that a pro...on of a molecule that is key to the ability// of r...break down toxins, and of cells to extract energy ...ators showed that ABCB6 is lodged within the outer...
...hat twins are performing on par with other childre...y the performance of the twins// has been found wa...e students. Researchers felt this was because twin...as well as have low educational motivation. The D...
...ates among younger and older Americans have been d...news: No one really knows why// . Those are the f... University of South Carolina and released Thursda... issue of the American Journal of Public Health. ...
Other Medicine News:Health News:Computer Tool Predicts Effectiveness Of Microbicides 2Health News:Computer Tool Predicts Effectiveness Of Microbicides 3Health News:ABCB6 Is Key to Production of Heme in Hemoglobin 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 2Health News:Most Suicide Rates Decline, but Findings Are Puzzling 3
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: